The Partnership for Drug-Free Kids, a national nonprofit dedicated to reducing substance abuse among adolescents, today launched a new multimedia campaign for teens that illustrates some of the pressures they face, including peer pressure to drink and use drugs, issues with body image and bullying, among others. The “Who Controls You” campaign breaks this month and was created pro-bono by advertising agency, Hill Holliday and award-winning, social media influencer, Maris Jones, as part of the Partnership’s Above the Influence (ATI) teen program.
“We are incredibly proud of this work. We struck gold when Hill Holliday collaborated with Adolescent Media and Maris Jones to bring this campaign to life,” said Chief Marketing Officer for the Partnership for Drug-Free Kids, Kristi Rowe. “Partnering with a young, talented social media influencer like Maris lent such a unique and authentic voice to this effort. Combining the extraordinary insight and passion of the Hill Holliday team with Maris’ distinct artistry brought an unexpected style to the campaign that makes this creative truly break through.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7103751-drug-free-partnership-who-controls-you/
The Ad Council, the largest producer of public service campaigns in the U.S., in partnership with Viacom, home to premier global brands in media and entertainment, and non-profit leader Facing Addiction today launched the PSA campaign “LISTEN” to ignite a national conversation about drug and alcohol addiction as a public health epidemic, and empower those impacted by substance use disorders.
While past PSA campaigns have traditionally focused on the perspective of those at risk, urging them to eliminate all substance use, “LISTEN” addresses the support system of people who are also affected by this crisis. Using powerful stories that portray the modern faces of addiction and recovery, the campaign looks to remove the stigma attached to substance misuse through the act of informed, compassionate listening. The campaign’s website, heretolisten.com, and Facing Addiction's Resource Hub provides important tools and information to help people start a productive conversation with their friends and loved ones and to support the more than 45 million Americans directly impacted by addiction.
To view the multimedia release go to:
http://www.multivu.com/players/English/8029751-ad-council-listen-psa-addiction-drug-alcohol-substance-abuse/
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
To help kids make healthful dietary choices, the U.S. Food and Drug Administration encourages kids to Read the Label!
The Nutrition Facts Label is a simple tool available on food and beverage packages. It lets kids know exactly what they’re eating and helps them choose and compare snacks and other foods. The earlier they start using the Nutrition Facts Label, the sooner they’ll be making choices that keep them feeling great and promote long-term good health!
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7106353-fda-national-childhood-obesity-month/
September is National Childhood Obesity Month. To help young people make healthy dietary choices, the U.S. Food and Drug Administration (FDA) encourages kids to Read the Label!
The Nutrition Facts label is a simple tool available on food and beverage packages. It lets kids know exactly what they’re eating and helps them choose and compare snacks and other foods. The earlier kids start using the Nutrition Facts label, the sooner they’ll be making choices that keep them feeling great and on the path to long-term good health!
To view the multimedia release go to:
http://www.multivu.com/players/English/7770751-fda-national-childhood-obesity-month/
Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses are the only lenses in the United States that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the Tecnis Symfony Toric IOL.
Cataracts are a common condition, with almost 4 million cataract surgeries performed each year, and that number is expected to increase.1 By age 80, more than half of all Americans either have a cataract or have had cataract surgery.2 However, cataracts do not just impact seniors. In 2016 it is estimated that nearly one in four cataract surgeries will be performed on people younger than 65.1 Many people who have cataracts experience other problems with their vision, such as presbyopia and astigmatism, which the Symfony lenses also address. Presbyopia, which affects most people over age 40, means people have lost the ability to focus on objects up close and often require glasses to perform near visual tasks. Astigmatism is when the cornea is misshapen, which causes blurry or distorted vision.
To view the multimedia release go to:
http://www.multivu.com/players/English/7870151-abbott-intraocular-lenses/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
Drugs are everywhere. The use of prescription painkillers has increased dramatically in recent years, and prescription drug abuse is now the nation’s fastest-growing drug problem. According to the U.S. Department of Health and Human Services, more than 5 million Americans misuse painkillers each month. Opioid painkillers—a class of very powerful and potentially addicting pain relievers—are the most common source of drug overdose deaths, resulting in more unintentional deaths than cocaine and heroin combined.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prescriptiondrugabuse/50825/
More than 46 million turkeys will be cooked this Thanksgiving holiday, according to the National Turkey Federation. In an effort to help protect Americans from foodborne illness during the Thanksgiving season, the Ad Council, the U.S. Department of Agriculture (USDA)’s Food Safety and Inspection Service, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), in partnership with Food Network Star’s Martie Duncan, are helping to dispel many of the common myths surrounding the preparation and serving of the holiday turkey meal.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59193-ad-council-usda-hhs-food-safe-families-public-service-thanksgiving
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
The U.S. Food and Drug Administration (FDA) Office of Women’s Health today released a new public service announcement (PSA) titled, “Use Medicines Wisely,” to help raise awareness about safe medication use.
Millions of people benefit from FDA approved medications and are living longer productive lives. However, when medications are used incorrectly, they can cause serious injuries, even death. Many of these injuries can be prevented.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/fda/50878/
